Open Access
Acta Pharmaceutica Sinica B, volume 10, issue 10, pages 1943-1953
Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
Mingxing Hu
1
,
Weilin Zhou
1
,
Yijie Wang
1
,
Dongping Yao
1
,
Tinghong Ye
1
,
Yang Yao
1
,
Bin Chen
1
,
Gongping Liu
2
,
Xifei Yang
3
,
Wei Wang
1
,
Yongmei Xie
1
3
Key Laboratory of Modern Toxicology of Shenzhen, Shenzhen Centre for Disease Control and Prevention, Shenzhen 518055, China.
|
Publication type: Journal Article
Publication date: 2020-10-01
Journal:
Acta Pharmaceutica Sinica B
scimago Q1
wos Q1
SJR: 3.035
CiteScore: 22.4
Impact factor: 14.7
ISSN: 22113835, 22113843
General Pharmacology, Toxicology and Pharmaceutics
Abstract
Cancer immunotherapy is revolutionizing oncology and has emerged as a promising strategy for the treatment of multiple cancers. Indoleamine 2,3-dioxygenase 1 (IDO1), an immune checkpoint, plays an important role in tumor immune escape through the regulation of multiple immune cells and has been regarded as an attractive target for cancer immunotherapy. Proteolysis Targeting Chimeras (PROTAC) technology has emerged as a new model for drug research and development for its advantageous mechanism. Herein, we reported the application of PROTAC technology in targeted degradation of IDO1, leading to the discovery of the first IDO1 PROTAC degrader 2c, which induced significant and persistent degradation of IDO1 with maximum degradation (dmax) of 93% in HeLa cells. Western-blot based mechanistic studies indicated that IDO1 was degraded by 2c through the ubiquitin proteasome system (UPS). Label-free real-time cell analysis (RTCA) indicated that 2c moderately improved tumor-killing activity of chimeric antigen receptor-modified T (CAR-T) cells. Collectively, these data provide a new insight for the application of PROTAC technology in tumor immune-related proteins and a promising tool to study the function of IDO1.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.